ADC Therapeutics Announces $325M Financing Agreement With HealthCare Royalty

  • ADC Therapeutics SA ADCT has entered into a royalty purchase agreement with HealthCare Royalty Partners for up to $325 million.
  • ADC Therapeutics will receive $225 million upon closing, with an additional $100 million in potential near-term milestone payments related to Zynlonta (loncastuximab tesirine).
  • In exchange, HealthCare Royalty will receive a 7% royalty on worldwide net sales and licensing revenue from Zynlonta, except greater China, Singapore, and South Korea.
  • HealthCare Royalty will also receive a 7% royalty on worldwide net sales and licensing revenue from Cami (camidanlumab tesirine) (subject to limited carve-outs). 
  • The royalty of 7% terminates upon payment of 2.25x to 2.50x the purchase price.
  • Zynlonta is an FDA-approved CD19-directed antibody-drug conjugate (ADC) for adult patients with relapsed or refractory (r/r) large B-cell lymphoma.
  • Cami is an ADC comprised of a monoclonal antibody that binds to CD25. It is being evaluated in a Phase 2 trial for R/R Hodgkin lymphoma and a Phase 1b trial as monotherapy and in combination with pembrolizumab in solid tumors.
  • Price Action: ADCT shares are up 8.81% at $28.16 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFinancingMoversTrading IdeasGeneralBriefslymphomaoncologyPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!